Evodiamine prevents dextran sulfate sodium-induced murine experimental colitis via the regulation of NF-κB and NLRP3 inflammasome - 06/01/19
, Naisheng Zhang a, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 11 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Evodiamine alleviated dextran sulfate sodium (DSS)-induced mice experimental colitis. |
• | Evodiamine suppressed pro-inflammatory cytokines through regulating NF-κB signal and NLRP3 inflammasome activation. |
• | Evodiamine modulated DSS-induced decrease in the expression of ZO-1 and occludin. |
• | Evodiamine re-balanced Escherichia coli and Lactobacillus levels. |
• | Evodiamine reduced the plasmatic lipopolysaccharide concentration. |
Abstract |
Evodiamine (EVO), an extraction from the traditional Chinese medicine Evodia rutaecarpa, has been reported to possess anti-inflammatory, anti-tumor and other pharmacological activities. However, the effectiveness of EVO to relieve dextran sodium sulfate (DSS)-induced ulcerative colitis (UC) has not been evaluated. In this study, the protective effects and mechanisms of EVO on DSS-induced UC mice were investigated. The results indicated that treatment with EVO ameliorated DSS-induced UC mice body weight loss, disease activity index (DAI), colon length shortening, colonic pathological damage, and myeloperoxidase (MPO) activity. The production of TNF-α, IL-1β and IL-6 was also significantly inhibited by EVO. Further mechanistic results showed that EVO restrained the inflammation by regulating NF-κB signal and NLRP3 inflammasome. Furthermore, results also showed that EVO contributed to the tight junction (TJ) architecture integrity by modulating the expression of zonula occludens-1 (ZO-1) and occludin during colitis. Surprisingly, treatment with EVO reduced the concentration of plasmatic lipopolysaccharide (LPS) and re-balanced the levels of Escherichia coli and Lactobacillus. These findings suggested that EVO may have a potential protective effect on DSS-induced colitis and may be useful for the prevention and treatment of UC.
Le texte complet de cet article est disponible en PDF.Keywords : Evodiamine, Colitis, Inflammation, Intestinal microbiota, Intestinal barrier
Plan
Vol 110
P. 786-795 - février 2019 Retour au numéro
Article précédent
- Manilkara zapota (L.) P. Royen leaf water extract triggered apoptosis and activated caspase-dependent pathway in HT-29 human colorectal cancer cell line
- Bee Ling Tan, Mohd Esa Norhaizan
- Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer
- Shaheen Mahira, Nagavendra Kommineni, Gulam Mohammed Husain, Wahid Khan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?